Somavert (pegvisomant) / Pfizer - LARVOL DELTA

Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas. (PubMed, Pituitary) - "In this series of predominantly mammosomatotroph adenomas in younger adults, combination PAS plus PEGV offers potential durable biochemical control, tumor stability and PEGV dose reduction in treatment-resistant acromegaly. Glucose monitoring during treatment is essential as concomitant use of PEGV does not appear to mitigate PAS-induced glycemic deterioration. Larger prospective studies are needed to better define predictors of response."

Journal • Retrospective data • Acromegaly • Cardiovascular • Endocrine Disorders • Hepatology • Metabolic Disorders • Oncology • Pain • IGF1

Growth Hormone Receptor Antagonism Extends Lifespan. (PubMed, Aging Cell) - "Somavert (Pegvisomant for injection), used for treating patients with acromegaly, is currently the only FDA approved GHA...Analysis of an independent cohort of 2-year-old mice revealed that GHA males and females were less frail with enhanced grip strength despite increased adiposity. These findings demonstrate for the first time that GH antagonism can improve health and extend lifespan."

Journal • Acromegaly • Endocrine Disorders • Obesity

Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System. (PubMed, Front Endocrinol (Lausanne)) - "Resistance to first-line medical treatment necessitates effective second-line therapies, including pasireotide long-acting release (PAS LAR) and pegvisomant (PEG). Compared to FGSRLs, PAS LAR provided better outcomes with higher costs. With limited options for second-line medical treatment in Brazil, the reimbursement of PAS LAR in acromegaly can be considered a cost-effective strategy for acromegaly patients."

HEOR • Journal • Acromegaly • Endocrine Disorders • Pituitary Gland Carcinoma

Management and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature. (PubMed, Endocrine) - "Pregnancy in acromegaly is generally characterized by clinical stability, supporting the safety of treatment withdrawal upon conception in most patients. While early therapy discontinuation is standard, SRL and/or PEG treatment is a viable option for patients requiring tumor and biochemical control. Individualized multidisciplinary management is essential."

Journal • Review • Acromegaly • Diabetes • Endocrine Disorders • Gestational Diabetes • Gynecology • Metabolic Disorders • Oncology • Pituitary Gland Carcinoma • SSTR

Impact of endoscopy and related technologies on indications for transsphenoidal pituitary surgery for growth hormone-producing pituitary neuroendocrine tumors in McCune-Albright syndrome: illustrative case. (PubMed, J Neurosurg Case Lessons) - "Surgical treatment was previously considered difficult in cases of GH-producing pituitary tumor associated with MAS. However, recent advances in transnasal endoscopic surgery, including drilling and neuronavigation techniques, have made surgical endocrine remission achievable in some cases. Therefore, surgical indications should be reconsidered even in patients undergoing medical therapy. https://thejns.org/doi/10.3171/CASE26521."

Journal • Genetic Disorders • Neuroendocrine Tumor • Oncology • Otorhinolaryngology • Pituitary Gland Carcinoma • Solid Tumor • IGF1

Acromegaly Secondary to Ectopic Growth Hormone-Releasing Hormone Secretion From Metastatic Bronchial Carcinoid Tumor: A Case Report. (PubMed, Cureus) - "She also continues to require long-term therapy with octreotide (Sandostatin) and pegvisomant to control IGF-1 levels. This case highlights the rarity of ectopic GHRH secretion from metastatic bronchial carcinoid tumors and emphasizes the importance of long-term surveillance and multidisciplinary management."

Journal • Acromegaly • Carcinoid Tumor • Endocrine Disorders • Lung Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • IGF1

Development and Characterization of a Long-Acting Allosteric Growth Hormone Receptor Antagonist for Acromegaly. (PubMed, Endocrinology) - "In cynomolgus monkeys, a single 10 mg/kg intravenous (IV) dose of MAR002 sustained ≥50% IGF-1 suppression for 36 days compared with 15 days for an equimolar pegvisomant dose, with comparable maximal lowering (∼80%). These findings support clinical evaluation of MAR002 as a next-generation long-acting GHRA for acromegaly, with potential for reduced dosing frequency and more consistent suppression of the GH-IGF-1 axis."

Journal • Acromegaly • Endocrine Disorders • Pituitary Gland Carcinoma • Rare Diseases • IGF1

Can acromegaly be controlled in all cases? (PubMed, J Neuroendocrinol) - "In this review, we will report on the most recent aims of treatment and cure in patients with acromegaly, on the efficacy and predictors of response to conventional treatments (such as first- and second-generation somatostatin receptor ligands and growth hormone receptor antagonist). A specific section will focus on the rarer aggressive disease pictures and on the treatment with systemic therapies (such as temozolomide and capecitabine) and on target therapies (such as neo-angiogenesis and immune checkpoint inhibitors)."

Clinical • IO biomarker • Journal • Review • Acromegaly • Endocrine Disorders • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Rare Diseases • Solid Tumor • IGF1 • SSTR

Acromegaly and Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical and Therapeutic Implications. (PubMed, Curr Obes Rep) - "Acromegaly is associated with IR, type 2 diabetes mellitus, hypertension and cardiovascular disease; however, acromegaly is inversely associated with VAT and MASLD. Further mechanistic and clinical studies are warranted to better elucidate the intriguing association between acromegaly and MASLD."

Journal • Review • Acromegaly • Cardiovascular • Diabetes • Endocrine Disorders • Fibrosis • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Solid Tumor • Type 2 Diabetes Mellitus • IGF1

Korean Regulatory Post Marketing Surveillance for Somavert (clinicaltrials.gov) - P=N/A | N=11 | Completed | Sponsor: Pfizer | Recruiting ➔ Completed | N=100 ➔ 11 | Trial completion date: Sep 2026 ➔ Nov 2025 | Trial primary completion date: Sep 2026 ➔ Nov 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acromegaly • Endocrine Disorders

High-yield soluble expression and affinity-tag-free purification of growth hormone receptor antagonist B2036 in Escherichia coli. (PubMed, Bioprocess Biosyst Eng) - "By removing protein refolding and metal-affinity chromatography, this simplified and robust workflow remarkably improves productivity and product quality, offering a cost-effective and scalable technical platform for large-scale manufacturing of pegvisomant biosimilars. Collectively, these findings provide a valuable reference for developing efficient soluble expression and downstream purification processes of other intrachain disulfide-bonded proteins in E. coli."

Journal • Acromegaly • Endocrine Disorders

Hyperprolactinaemia masked by the hook effect in a patient with a giant prolactinoma with growth hormone co-secretion. (PubMed, BMJ Case Rep) - "She was treated with cabergoline, leading to substantial clinical improvement and progressive decrease in tumour size and prolactin...She was switched to pegvisomant therapy, resulting in insulin-like growth factor I normalisation. This case emphasises the critical importance of recognising the hook effect artefact in patients with large sellar masses. Slow uptitration of dopamine agonist therapy is advisable in patients with large tumours to minimise the risks of cerebrospinal fluid leak, apoplexy and herniation."

Journal • Endocrine Disorders • Gynecology • Oncology • Pain

Authors' reply to the letter to the editor by Fedai et al.: "Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort". (PubMed, Pituitary) - No abstract available

Journal • Monotherapy • Acromegaly • Endocrine Disorders

Beyond biochemical control: headache resolution with pasireotide in a patient with acromegaly and residual tumor. (PubMed, JCEM Case Rep) - "Despite transsphenoidal surgery, radiotherapy, and sequential medical therapy with octreotide, cabergoline, and pegvisomant over 3 years, insulin-like growth factor 1 (IGF-1) levels remained elevated and headache burden persisted. Initiation of pasireotide long-acting release was followed by rapid normalization of IGF-1 levels and complete resolution of headache, with improvement in other acromegaly related symptoms. This case supports the potential role of pasireotide in selected patients with biochemically and clinically treatment-resistant acromegaly and contributes to the growing real-world evidence regarding its use in patients with residual disease in surgically challenging locations."

Journal • Acromegaly • Endocrine Disorders • Oncology • Pain • Pituitary Gland Carcinoma • IGF1

Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years. (PubMed, J Clin Endocrinol Metab) - "Once-daily oral paltusotine treatment was well tolerated and resulted in long-term disease control, including biochemical, symptom, and pituitary tumor stability, for up to 4 years."

Journal • Acromegaly • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • IGF1 • SSTR

Approach to the patient: Precision Medicine-Guided Evaluation and Treatment of Acromegaly. (PubMed, J Clin Endocrinol Metab) - "Precision medicine has become a practical reality in acromegaly. A biomarker-guided strategy improves therapeutic efficiency and should be incorporated into contemporary clinical practice."

Journal • Acromegaly • Endocrine Disorders • Oncology

Combination therapy of pasireotide and pegvisomant for aggressive acromegaly with an immature PIT1-lineage PitNET. (PubMed, Endocrinol Diabetes Metab Case Rep) - "In patients with predictors of poor response to first-generation somatostatin analogs, such as T2-weighted MRI hyperintensity and poor GH suppression during acute octreotide testing, early consideration of pasireotide (PAS) or combination therapy with PAS and pegvisomant (PEG) may be appropriate. In this case, PAS up to 60 mg every 4 weeks failed to adequately control IGF-1 levels, whereas subsequent combination therapy with PAS and PEG achieved biochemical remission and tumor stabilization, highlighting the potential role of combination strategies in aggressive acromegaly."

Journal • Acromegaly • Endocrine Disorders • Neuroendocrine Tumor • Oncology • Rare Diseases • Solid Tumor • IGF1 • SSTR

Combination Therapy with Pasireotide LAR and Pegvisomant in Treatment-Resistant Acromegaly: A Case Series (ENDO 2026) - " 5 pts, 4 F, 1M (age 15-44), with somatotroph (1) or mammosomatotroph (4) adenomas, 3 uncontrolled on PAS-LAR, 1 uncontrolled on octreotide LAR+PEGV, and 1 uncontrolled on maximum octreotide LAR, demonstrated significant biochemical improvement on PAS-LAR (40 or 60 mg every 28 days)+ PEGV treated over a median of 3.0 years, range 2.2-5.2 years. Combination PAS-LAR and PEGV is a viable long-term option for treatment-resistant acromegaly, offering meaningful biochemical improvement, maintenance of tumor stability, and potential PEGV dose reduction. Side effects do not seem to be potentiated by combination therapy, but PEGV did not prevent PAS-related hyperglycemia in our pts. Severe acromegaly may (at least temporarily) respond to higher doses of PAS-LAR + PEGV while awaiting repeat surgery and/or radiation."

Clinical • Combination therapy • Acromegaly • Cardiovascular • Diabetes • Endocrine Disorders • Gastroenterology • Metabolic Disorders • IGF1 • SSTR • SSTR2

Comparative Efficacy and Safety of Oral vs Injectable Medical Therapies for Acromegaly: A Systematic Review and Network Meta-Analysis (ENDO 2026) - "SUCRA rankings favored Pasireotide, paltusotine, pegvisomant for efficacy, while oral octreotide ranked highest for safety and patient preference, reflecting reduced injection-site reactions and improved treatment acceptability. Conclusion This network meta-analysis demonstrates that while pasireotide and pegvisomant provide the highest efficacy, paltusotine emerges as the most effective oral therapy, offering a favorable balance of biochemical control, safety, and patient acceptability."

Retrospective data • Review • Acromegaly • Endocrine Disorders • IGF1

MON-030 - Eleven Years of Primary Medical Therapy with Somatostatin Analogs and Pegvisomant in A Young Man with Acromegaly (ENDO 2026) - "He was started on octreotide long-acting release, later switching to lanreotide Autogel at a dose of 120 mg every 4 weeks...Treatment options of surgery, addition of cabergoline, and switch to pasireotide have all been discussed and recommended to avoid complications of GH/IGF-1 excess, but the patient has so far continued to decline these options as he overall feels well... To our knowledge, this is the longest reported case of primary medical therapy in the treatment of acromegaly. While some studies have demonstrated effectiveness of long-term medical therapy for IGF-1 normalization and tumor shrinkage, our patient continues to have markedly elevated IGF-1, placing him at risk for continued complications of acromegaly. Our case underscores the need for individualized treatment approaches and counseling strategies for biochemical control in patients with acromegaly who do not undergo surgery."

Acromegaly • Cardiomyopathy • Endocrine Disorders • Metabolic Disorders • Pituitary Gland Carcinoma • IGF1

Chronic Growth Hormone Excess Drives Premature Immune Aging by Reshaping Splenic Architecture and B Cell Subsets (ENDO 2026) - "Given that GH signaling is pharmacologically targetable, these data support GH antagonism (Pegvisomant; an FDA-approved drug) as a potential strategy to preserve immune healthspan during aging. Acknowledgments: This work is supported in part by the NIH grant AG059779, P30AG13319, and the State of Ohio's Eminent Scholar Program includes a gift from Milton and Lawrence Goll Targeted Conference: ENDO Annual Meeting to be held in Chicago, Illinois, USA, from June 13 to June 16, 2026."

CD21 • FCER2

Determining the Insertion Site of the Bovine Growth Hormone and Growth Hormone Receptor Antagonist Transgenes in Mice (ENDO 2026) - "The growth hormone (GH) antagonist, which was developed into the drug pegvisomant, was initially discovered by expressing a mutated GH gene in transgenic mice that led to decreased growth...Acknowledgments: This work is supported in part by the NIH grant AG059779, and the State of Ohio's Eminent Scholar Program which includes a gift from Milton and Lawrence Goll. We would like to acknowledge the University of Michigan Transgenic Animal Model Core for their assistance with this work."

Preclinical • Genetic Disorders • Obesity

Eleven Years of Primary Medical Therapy with Somatostatin Analogs and Pegvisomant in A Young Man with Acromegaly (ENDO 2026) - "He was started on octreotide long-acting release, later switching to lanreotide Autogel at a dose of 120 mg every 4 weeks...Treatment options of surgery, addition of cabergoline, and switch to pasireotide have all been discussed and recommended to avoid complications of GH/IGF-1 excess, but the patient has so far continued to decline these options as he overall feels well... To our knowledge, this is the longest reported case of primary medical therapy in the treatment of acromegaly. While some studies have demonstrated effectiveness of long-term medical therapy for IGF-1 normalization and tumor shrinkage, our patient continues to have markedly elevated IGF-1, placing him at risk for continued complications of acromegaly. Our case underscores the need for individualized treatment approaches and counseling strategies for biochemical control in patients with acromegaly who do not undergo surgery."

Acromegaly • Cardiomyopathy • Endocrine Disorders • Metabolic Disorders • Pituitary Gland Carcinoma • IGF1

Blocking Growth Hormone Receptor Restores Chemo-Immunotherapy Sensitivity of Tumors in Mouse Model of Lung Cancer (ENDO 2026) - "In parallel, we assessed the effects of the GHR antagonist, Pegvisomant, on immune checkpoint gene expression in human and murine lung cancer cells. Preclinical in vivo studies were conducted using lung tumor engrafted wild-type and GHR antagonist (GHA) mice, treated with either cisplatin, or anti-PD-1 antibodies, or both...Altogether, here we present the first report that targeting the GHR signaling promotes immune therapy response in pre-clinical cancer model. Collectively, these results provide the molecular rationale for targeting GHR as a novel adjuvant strategy to significantly improve chemo-immunotherapy outcomes in NSCLC."

IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CXCL10 • CXCR3 • IGF1 • PD-L1 • PD-L2

Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in Combination with Cabergoline for the Treatment of Patients with Acromegaly (ENDO 2026) - P2 | "At enrollment in Edge, all patients were candidates for combination drug therapy: patients were either suboptimally controlled on an injected SRL (octreotide or lanreotide) alone or in combination with cabergoline, or they required combination therapy or pasireotide to achieve normal IGF-I levels...Adjunctive treatment (eg, cabergoline, pegvisomant) was allowed as of Week 12 in patients who did not attain normal IGF-I levels on the maximum dose of paltusotine...One serious drug-related AE (cholelithiasis) was reported, and 1 patient discontinued the study due to an AE (headache; considered possibly related to study medication). In patients with acromegaly who were candidates for combination therapy based on treatment history, long-term results (up to 4 years) show that once-daily oral paltusotine in combination with cabergoline was well tolerated, with improved biochemical control and no new safety findings."

Clinical • Combination therapy • Acromegaly • Endocrine Disorders • Gastroenterology • Musculoskeletal Pain • IGF1 • SSTR